top of page
  • Writer's pictureBiomedical Bonding

Final validation assessment of Bonevolent™ - AdhFix

BMB delivers over 200 sterilized AdhFix products to Rise Research Institutes of Sweden for final biocompatibility and animal transplantation assessments. With successful completion anticipated by the second half of this year, BMB will be prepared to undertake next big milestone: First-in-Human clinical trials.


Context: Bonevolent™ - AdhFix is BMB’s first-mover product proposition to enter the orthopedic market. It is an injectable and universal composite plating technology that has the potential to replace many of the existing metal plates used for low-loadbearing fractures.


bottom of page